
    
      the age of the patients ranged from 18 to 77 years. After a run-in period of 4 weeks, during
      which all of the patients received budesonide twice a day, they were randomized into one of
      the treatment groups for 12 weeks, twice a day.

      The primary outcome measures were FEV1, FVC and morning PEF. We performed an
      intention-to-treat analysis of the data.
    
  